Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Sees Significant Increase in Short Interest

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 35,280 shares, a growth of 99.8% from the June 15th total of 17,654 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 103,592 shares, the days-to-cover ratio is currently 0.3 days.

Otsuka Price Performance

Shares of OTSKY stock opened at $33.69 on Thursday. The firm has a market cap of $36.19 billion and a price-to-earnings ratio of 14.22. The stock’s fifty day simple moving average is $34.48 and its 200 day simple moving average is $33.08. Otsuka has a one year low of $21.68 and a one year high of $37.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67.

Otsuka (OTCMKTS:OTSKY) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.16. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. The firm had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. On average, analysts expect that Otsuka will post 1.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Otsuka has a consensus rating of “Hold”.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.